Adenoviral Vector CDMOs with Clean FDA Inspection History
Adenoviral vector CDMOs make replication-deficient adenovirus for gene therapy and vaccines, using producer cell lines (e.g. HEK293), suspension bioreactors, and chromatographic purification. The platform reaches high titers, which suits vaccine-scale demand.
Selecting an adenoviral CDMO turns on serotype and producer-line experience, suspension scale, full/empty particle control, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 6 NAI (no action), 13 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (14), UNITED KINGDOM (10), Belgium (4), Italy (4), Netherlands (3).
Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing contract manufacturers only.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
SK
Dublin, Ireland. Rancho Cordova, CA. King of Prussia, PA. Houston, TX. Korea. France.
|
79.5 | 100.0 | — | None on file | Available | — |
| 2 |
ET
Jumet, BE
|
78.1 | 100.0 | 0 insp · 4 GMP | None on file | — | — |
| 3 |
AD
London, United Kingdom
|
78.1 | 100.0 | 0 insp · 2 GMP | None on file | — | — |
| 4 |
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
|
77.6 | 93.2 | 19 insp · 10 GMP | 2026-06-30 · NAI | Available | 2 programs |
| 5 |
RT
|
71.1 | 100.0 | 0 insp · 4 GMP | None on file | — | 1 program |